Taiwan's chip dominance becomes global security, economic flashpoint
WASHINGTON, June 12 (UPI) -- Taiwan may be an island of just over 23 million people, but what happens there could ripple across the global economy. The small democratic nation produces the vast majority of the world's most advanced semiconductors -- chips that are used in everything from smartphones and electric cars to defense systems and spacecraft.
Taiwan Semiconductor Manufacturing Co. Ltd. "produces roughly 90% of the most sophisticated computer chips, and the loss of that would be devastating," said Steven David, a professor of political science at Johns Hopkins University in Baltimore. "We can't get around without it."
For Taiwan, this manufacturing dominance isn't just economic -- it's strategic. Analysts call it the island's "silicon shield." The world relies heavily on Taiwan's chips, which deters China from launching a military attack and pushes allies like the United States to come to Taiwan's defense.
The geopolitical stakes around Taiwan's semiconductor dominance have soared as China escalates military pressure, through increased fighter jet incursions, large-scale naval drills and explicit threats of reunification.
U.S. lawmakers from both parties have increasingly voiced concern that a Chinese invasion could upend global chip supply chains and empower Beijing with outsized economic leverage.
"It [would be] monumentally stupid to try to keep something as fragile as chips production going during the time of war," said Kitsch Liao, associate director of the Atlantic Council's Global China Hub. "One stray shell could destroy that plant and you're done."
The United States has taken steps to address this vulnerability. In 2022, former President Joe Biden signed the CHIPS and Science Act, allocating $280 billion to support domestic semiconductor manufacturing and research, including subsidies for Taiwan Semiconductor to build a plant in Phoenix.
In March, President Donald Trump announced a new $100 billion deal with the company to dramatically expand its manufacturing presence in the United States.
"America is building plants with Taiwanese investment and cooperation in Arizona and elsewhere, but it would still be devastating," David said, referring to the potential impact of a Chinese attack on chip production.
Taiwan's government has had to carefully balance cooperation with the United States against growing fears at home that shifting too much chip production abroad could weaken its security.
Taiwan's two main political parties, the Kuomintang, or KMT, and the Democratic Progressive Party, or DPP, have debated the best approach to cross-strait relations.
While the KMT supports closer ties with China, the DPP, which currently holds the presidency under Lai Ching-te, has leaned toward reinforcing Taiwan's democratic independence and diversifying trade, actions that could increase already mounting pressure from China.
"If China does successfully invade Taiwan and takes over the TSMC plant, it won't be able to use the plant the way Taiwan does," David said. "But it would deny its use to others, and that would be devastating to the world economy. Several percentages of world GDP would drop as a result."
Analysts worry that even the threat of invasion could destabilize markets. Blockades or gray zone tactics by Beijing, short of all-out war, could still limit Taiwan Semiconductors' ability to export.
"Any erosion in Taiwan's ability to trade with the rest of the world would have a significant impact on the global economy," said Jack Burnham, a research analyst at the Washington-based Foundation for Defense of Democracies.
"It would disrupt the flow of semiconductors to a variety of different industries that are incredibly valuable to the United States, its allies and partners, and the global community."
Taiwan has long been one of the most contentious issues in United States-China relations. After the Chinese Civil War, the Nationalist government fled to Taiwan in 1949, and the Chinese Communist Party established the People's Republic of China on the mainland. Since then, Beijing has claimed Taiwan as an inalienable part of its territory.
In 1979, the United States. ended formal diplomatic recognition of Taipei in favor of Beijing, but passed the Taiwan Relations Act, which commits the United States to help Taiwan maintain a "sufficient self-defense capability."
The United States, though, has remained deliberately vague about whether it would come to Taiwan's defense in the event of a Chinese invasion -- a policy known as strategic ambiguity.
But as threats of an invasion increased, this stance continued to be tested. In a speech in Singapore last month, Defense Secretary Pete Hegseth vowed that "devastating consequences" could result should China seek to "conquer" Taiwan, warning that an invasion could be "imminent."
Beyond semiconductor and chips manufacturing, Taiwan remains a core interest in the Indo-Pacific region. The island sits at the heart of the "first island chain," a line of U.S.-aligned territories stretching from Japan to the Philippines.
If China were to take over Taiwan, experts warned it could use the island as a launchpad to project power deep into the Pacific, posing a direct challenge to U.S. interests.
"Should China be successful [in a reunification scenario], it would have a significant impact on the lives of everyday Americans -- both in their wallets and in the political situation they find themselves in," Burnham said.
"What's at stake when it comes to Taiwan is the free flow of trade, a significant part of the American economy, and the health and stability of the United States' key allies and partners in the region."
Copyright 2025 UPI News Corporation. All Rights Reserved.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
China Boosts Credit with $204B Bond Push--But Borrowing Stays Muted
China's credit growth picked up in Maybut the momentum came from Beijing, not the private sector. The People's Bank of China reported nearly 1.5 trillion yuan ($204 billion) in government bonds were sold last month, roughly 20% higher than a year ago. That marks the third time in 2025 bond sales have topped 1 trillion yuan in a single month. The surge helped lift total aggregate financing to 2.29 trillion yuan, an increase from 2 trillion yuan in May 2024. On the ground, though, the appetite for new borrowing looks subdued. Households took out just 54 billion yuan in new loans last month, bringing the year-to-date total to 572 billion yuanthe lowest since at least 2009. New loans from financial institutions also fell, landing at 620 billion yuan, well below last year's 945 billion yuan for the same period. This comes even after the PBOC announced sweeping monetary easing in early May, including across-the-board rate cuts and liquidity moves that could inject 2.1 trillion yuan into the economy. According to Bloomberg Economics' Eric Zhu, May's numbers suggest the government is delivering on its stimulus plans, but the response from households and businesses remains cautious. For global investors watching China's recovery story, the next leg of growth may depend on whether demand strengthens beyond public-sector activity. Companies with strong exposure to the Chinese consumer, including Tesla (NASDAQ:TSLA), could be watching for early signs of a turn in private-sector sentiment. This article first appeared on GuruFocus.
Yahoo
an hour ago
- Yahoo
AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates. Under the deal, AstraZeneca will pay an upfront fee of $110m, along with milestone payments of $1.62bn. CSPC are also in line to receive $3.6bn in sales milestone payments. AstraZeneca and CSPC will discover and develop pre-clinical candidates for multiple targets, which, according to the companies, will have the 'potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases'. CSPC will use its AI-powered drug discovery platform, which uses the technology to analyse the binding patterns of target proteins with existing compound molecules. The AI models work out targeted optimisation, advancing small molecules with the best developability. For any candidates identified via the research partnership, AstraZeneca will have the right to exercise options for exclusive licences to develop and commercialise candidates worldwide. AstraZeneca's executive vice president and biopharmaceuticals R&D head Sharon Barr said: 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases, which impact over two billion people globally. 'Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines.' The partnership marks the second time this year AstraZeneca has invested resources in China. In March 2025, the drugmaker revealed plans to infuse $2.5bn over the next five years in Beijing to establish an R&D hub. China is enjoying a fruitful alliance with Western big pharma companies, despite a frosty relationship with US President Trump's administration, mainly due to the BIOSECURE ACT, which is admittedly now in legislative limbo. Licensing deals between US and Chinese biopharma companies hit record highs last year, up 280% from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio


UPI
an hour ago
- UPI
Oil and gold up, stocks down in response to Israeli attack on Iran
A board on the floor of the New York Stock Exchange in New York City shows gold's activity (February 2020). Gold was a bright spot for investors Friday, as gold futures were $3,448.80 at 11:28 a.m., just a tick down from its $3465.80 peak of the day. File Photo by John Angelillo/UPI | License Photo June 13 (UPI) -- Oil and gold prices jumped Friday as stocks fell in response to Israeli airstrikes on Iran Thursday night. Crude oil futures have been in the green all day so far, with an open of $68.90 that rose as high as $77.62 before falling back a bit, as by 11:29 a.m. the price was $72.24, which still stands as a 6.17% upsurge. The stock market on the other hand is down all around, with the Dow Jones Industrial Average being the hardest hit so far, down to 42,509.25 as of 11:36 a.m., which is actually up from its worst point of the day when it plummeted to 42, 259.84 at 10:30 a.m. The Nasdaq Composite also crept up from a 10:30 a.m. low of 19,381.74 to 19,539.49 at 11:34 a.m., which is still down 0.63%. The S&P 500 also saw a 10:30 a.m. worst at 5,975.91, but rose to 6,012.26 by 11:36 a.m., still pointed downwards at 0.55%. Aside from oil, gold has been a bright spot for investors Friday, as gold futures were $3,448.80 at 11:28 a.m., just a tick down from its $3465.80 peak of the day so far, still up 1.36% and not far from its record high of $3,500.05, set in April. Israel reported to have attacked nuclear facilities and missile factories in Iran Thursday that also killed some Iranian military commanders. Iran has since retaliated by launching several drones at Israel in what could evolve into a prolonged conflict.